A new, double-layered nanoparticle vaccine made with peptides has been found to effectively protect mice against influenza A virus, according to a study led by Georgia State University.
If seasonal flu vaccines are mismatched against circulating influenza strains, they provide low effectiveness and limited protection, which could lead to influenza epidemics and pandemics. Nanotechnology provides a promising approach for developing new influenza vaccines, and the double-layered nanoparticle vaccine created in this study shows strong potential for combatting influenza viruses.
To construct the nanoparticles (nanoscale-sized particles) for this vaccine, the researchers used peptides, compounds consisting of two or more amino acids linked in a chain, because they are much smaller than proteins. The nanoparticles mimic the biological cues of viruses and initiate danger signals that activate immune responses.
Peptides from nucleoprotein
Each double-layered nanoparticle has a core made of peptides from nucleoprotein (NP), an internal influenza protein that has been found to produce cross-protection against influenza virus by inducing T-cell immune responses.
The nanoparticle also has an outside coating made of four peptides from the ectodomain of influenza A M2 protein (M2e), an evolutionarily conserved region in most human seasonal influenza A viruses and a promising target for universal flu vaccines. The M2e sequences came from human, swine and avian influenza strains.
The peptide-only, double-layered nanoparticles, which were delivered by skin vaccination with a dissolvable microneedle patch, induced robust, long-lasting protective immunity and guarded mice against exposure to influenza A virus. The findings are published in the journal Proceedings of the National Academy of Sciences.
"The adaptive immune system includes B lymphocytes mediating antibody responses and T lymphocytes mediating cellular responses," said Dr. Bao-Zhong Wang. "Our novel nanoparticles trigger immune responses of both immune branches. We have seen the synergistic role of the two branches in providing broad cross-protection against a wide range of diverse influenza virus challenges after vaccination with these layered peptide nanoparticles."
Double-layered nanoparticle vaccine
The researchers administered the double-layered nanoparticle vaccine to mice using a microneedle patch, which offers advantages over traditional, intramuscular injection, and then exposed them to influenza A virus to see if the vaccine-induced protection against the virus.
The researchers based their vaccine design on findings from previous studies. Other researchers have found that NP can induce T-cell immune responses. Also, this team, along with other scientists, have found that M2e enhances immune responses.
In future studies, the researchers plan to build upon this double-layered nanoparticle vaccine by adding the inside portion of the influenza virus's surface protein, which is known as the stalk, to the nanoparticle vaccine coating.
Seasonal flu vaccines provide protective immunity against influenza viruses by targeting the exterior head of this surface protein, hemagglutinin. The researchers hope to administer the vaccine using a microneedle patch. Their goal is to make a strong universal vaccine with a better delivery approach.
This vaccine approach could also be used to develop vaccines for other pathogens and cancers. The layered, peptide nanoparticles were found to be potent and stable, which indicates potential applications for other peptide-based vaccines and peptide drug delivery.